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Computational Protein Design to Re-Engineer Stromal Cell-Derived Factor-1α
Factor-1
(SDF) Generates an Effective and Translatable Angiogenic Polypeptide Analog
Abstract
BACKGROUND: Experimentally, exogenous administration of recombinant stromal cell-derived factor-1α
(SDF) enhances neovasculogenesis and cardiac function after myocardial infarction. Smaller analogs of
SDF may provide translational advantages including enhanced stability and function, ease of synthesis,
lower cost, and potential modulated delivery via engineered biomaterials. In this study, computational
protein design was used to create a more efficient evolution of the native SDF protein.
METHODS AND RESULTS: Protein structure modeling was used to engineer an SDF polypeptide analog
(engineered SDF analog [ESA]) that splices the N-terminus (activation and binding) and C-terminus
(extracellular stabilization) with a diproline segment designed to limit the conformational flexibility of the
peptide backbone and retain the relative orientation of these segments observed in the native structure of
SDF. Endothelial progenitor cells (EPCs) in ESA gradient, assayed by Boyden chamber, showed
significantly increased migration compared with both SDF and control gradients. EPC receptor activation
was evaluated by quantification of phosphorylated AKT, and cells treated with ESA yielded significantly
greater phosphorylated AKT levels than SDF and control cells. Angiogenic growth factor assays revealed
a distinct increase in angiopoietin-1 expression in the ESA- and SDF-treated hearts. In addition, CD-1 mice
(n=30) underwent ligation of the left anterior descending coronary artery and peri-infarct intramyocardial
injection of ESA, SDF-1α, or saline. At 2 weeks, echocardiography demonstrated a significant gain in
ejection fraction, cardiac output, stroke volume, and fractional area change in mice treated with ESA
compared with controls.
CONCLUSIONS: Compared with native SDF, a novel engineered SDF polypeptide analog (ESA) more
efficiently induces EPC migration and improves post-myocardial infarction cardiac function and thus
offers a more clinically translatable neovasculogenic therapy.
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Abstract
BACKGROUND—After ischemic injury, cardiac secretion of the potent endothelial progenitor
stem cell (EPC) chemokine SDF stimulates endogenous neovascularization and myocardial repair,
a process insufficiently robust to repair major infarcts. Experimentally, exogenous administration
of recombinant SDF enhances neovasculogenesis and cardiac function after MI. However, SDF
has a short half-life, is bulky, and very expensive. Smaller analogs of SDF may provide
translational advantages including enhanced stability and function, ease of synthesis, lower cost,
and potential modulated delivery via engineered biomaterials. In this study, computational protein
design was used to create a more efficient evolution of the native SDF protein.
METHODS and RESULTS—Protein structure model was used to engineer an SDF polypeptide
analog (ESA) that splices the N-terminus (activation and binding) and C-terminus (extracellular
stabilization) with a diproline segment designed to limit the conformational flexibility of the
peptide backbone and retain the relative orientation of these segments observed in the native

Corresponding Author: Y. Joseph Woo, M.D. 3400 Spruce St. 6 Silverstein Philadelphia, PA 19104 Phone: 215-662-2956 Fax:
215-349-5798 wooy@uphs.upenn.edu.
Disclosures
None.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Hiesinger et al.

Page 2

structure of SDF. EPCs in ESA gradient, assayed by Boyden chamber, showed significantly
increased migration compared to both SDF and control gradients (ESA 567±74 cells/HPF vs SDF
438±46 p=0.037; vs Control 156±45 p=0.001). EPC receptor activation was evaluated by
quantifying phosphorylated AKT. ESA had significantly greater pAKT levels than SDF and
control (1.64±0.24 vs 1.26±0.187, p=0.01; vs. 0.95±0.08, p<0.001). Angiogenic growth factor
assays revealed a distinct increase in Angiopoietin-1 expression in the ESA and SDF treated
hearts. Also, CD-1 mice (n=30) underwent LAD ligation and peri-infarct intramyocardial injection
of ESA, SDF-1α, or saline. At 2 weeks, echocardiography demonstrated a significant gain in EF,
CO, SV, and Fractional Area Change (FAC) in mice treated with ESA when compared to controls
and significant improvement in FAC when compared to SDF treated mice.
CONCLUSION—When compared to native SDF, a novel engineered SDF polypeptide analog
(ESA) more efficiently induces EPC migration and improves post-MI cardiac function, and thus
offers a more clinically translatable neovasculogenic therapy.
Keywords
Angiogenesis; Cardiac Surgery; Computer-Based Model; Coronary Microvascular Function;
Endothelial Progenitor Cells

Background
More people die annually from cardiovascular disease than from any other cause. The World
Health Organization estimates that more than 17 million people per year die from
cardiovascular disease. Of these deaths, an estimated 7.2 million were due to ischemic heart
disease. An estimated 80,000,000 American adults (approximately 1 in 3) have at least one
type of cardiovascular disease with more than 22,000,000 suffering from either coronary
heart disease or heart failure.1
Treatments for ischemic heart disease often fail because they do not address the underlying
ventricular cellular pathophysiology and, most importantly, do not restore microvascular
perfusion, which has been shown to be a critical, independent predictor of ventricular
remodeling as well as reinfarction, heart failure, and death.2,3 On the other hand, postinfarction patients who develop robust angiographic collateralization manifest improved
regional ventricular function, suggesting an important role of the native revascularization
process.4 Current therapeutic options for ischemic heart disease are only capable of
intervening in relatively large arteries, leaving pervasive microvascular dysfunction
unaddressed. This is important because microvascular integrity, specifically microvascular
blood velocity and flow, predicts functional recovery of ischemic myocardium.5-9 In
addition, current interventions are instituted relatively late in the overall timecourse of the
disease process with macrorevascularization possible in only 63–80% of patients with
ischemic heart disease.10 Even with re-establishment of epicardial coronary artery flow
through thrombolysis, percutaneous intervention, or bypass grafting, a paucity of patent,
functional microvasculature remains. Angiogenic cytokine therapy is a
microrevascularization strategy that can serve as a primary therapy at any point in the
disease process and can be employed synergistically with traditional coronary
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revascularization methods.11 A wide variety of cytokines and microrevascularization
techniques have been employed with varying degrees of success.12-15
Stromal cell-derived factor-1α (SDF) is a powerful chemoattractant and considered to be
one of the key regulators of hematopoietic stem cell trafficking between the peripheral
circulation and bone marrow. It has been shown to effect EPC proliferation and mobilization
to induce vasculogenesis, and is significantly upregulated in response to both myocardial
ischemia and infarction.16, 17 SDF, a 67 amino acid protein, is also remarkably conserved
among species; a single amino acid substitution is all that differentiates the human and
murine sequences.18 Experimentally, delivery of SDF to ischemic myocardium has been
shown to increase circulating EPCs, significantly enhance myocardial endothelial progenitor
cell density, increase vasculogenesis, and augment myocardial function by enhancing
perfusion, reversing cellular ischemia, increasing cardiomyocyte viability, and preserving
ventricular geometry.19, 20
However, recombinant SDF is quickly degraded by multiple proteases18, 21, has a large and
complex tertiary structure involving multiple disulfide linkages22, and is very expensive
since it is a recombinant protein. Smaller analogs of SDF may provide translational
advantages including enhanced stability and function, ease of synthesis, lower cost, and
potential modulated delivery via engineered biomaterials.23, 24 In the present study, we set
out to design and engineer a minimized highly efficient polypeptide analog of the SDF
molecule using computational molecular modeling and design. The primary design goal was
to remove the large, central β-sheet region and link the native N-terminus (responsible for
receptor activation and binding) and the C-terminus (responsible for extracellular
stabilization) while maintaining functionality and the approximately perpendicular
orientation between the two termini.22 Two disulfide bonds located in the large central βsheet region help to maintain the conformation of native SDF. In order to recover a similar
conformation after excision of this portion of the protein, proline residue linkers were
considered to connect the N- and C-termini. The cyclic proline residue limits the
conformational space accessible to the polypeptide. Loop modeling calculations revealed the
variability of conformations explored by linkers comprising different numbers of proline
residues. A designed diproline linker yielded energetic and conformational advantages
resulting in a small, low molecular weight engineered SDF polypeptide analog (ESA) that
was shown to have activity comparable to or better than recombinant human SDF both in
vitro and in a murine model of ischemic heart failure.

Methods
Computational Protein Design, Modeling, and Synthesis
Loop modeling calculations were carried out using the program MODELLER, which
implements a loop modeling algorithm that consists of an optimization of a defined segment
of protein structure in a fixed environment, guided by a pseudo energy scoring function.25
Fifty different structures for a one, two, and three proline residue linker were created while
constraining the coordinates of the remainder of the protein. The conformation with the
lowest effective energy (best score) was analyzed using Molprobity, which provides detailed
all-atom contact analysis of steric interactions, dihedral angles, and possible hydrogen bonds
Circulation. Author manuscript; available in PMC 2014 August 18.
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and van der Waals contacts.26 After the amino acid sequence of the newly designed ESA
peptide had been computationally designed and analyzed, it was synthesized utilizing solid
phase peptide synthesis which involves the incorporation of N-a-amino acids into a peptide
of any desired sequence with one end of the sequence remaining attached to a solid support
matrix. After the desired sequence of amino acids has been obtained, the peptide is removed
from the polymeric support.
Cell Isolation
Bone marrow mononuclear cells (MNC) were isolated from the long bones of adult male
Green Fluorescent Protein (GFP)-Wistar rats by density-gradient centrifugation with
Histopaque 1083 (Sigma) and cultured in Endothelial Basal Medium-2 supplemented with
EGM-2 Singlequot (Lonza) containing hEGF, FBS, VEGF, hFGF-B, R3-IGF-1, ascorbic
acid, heparin, gentamicin, and amphotericin-B. The combination of endothelial specific
media and the removal of nonadherent MNCs was intended to select for the EPC phenotype.
Functional Characterization of Isolated EPCs by Boyden Chamber Assay
Boyden chambers (Neuro Probe) were employed to assess EPC migration. Briefly, 8 μm
filters were loaded into control and experimental chambers. Fourteen day EPCs cultured in
endothelial specific media on vitronectin coated plates were trypsinized, counted, and
brought to a concentration of 90cells/μl in Dulbecco's phosphate buffered saline (DPBS).
The bottom chamber of the control and experimental chambers were loaded with DPBS,
100ng/ml recombinant SDF (R&D systems) in DPBS, or 100ng/ml ESA in DPBS. A 560μl
cell suspension was added to the top chamber of each. All three chambers were incubated at
37°C, 5%CO2 for 4 hours. The cells remaining in the top chamber were wiped clean with a
cotton swab and the filter was removed. Slides were visualized on a DF5000B Leica
Fluorescent scope and analyzed via LASAF version 2.0.2 (Leica) software. Boyden chamber
analysis was performed in triplicate. Additional Boyden Chamber assays were run to
generate a dose/response curve comparing molar equivalents of ESA and SDF. A series of
progressively increasing ESA and SDF gradients (0.625nM, 1.25nM, 2.5nM, 5nM, 12.5nM,
20nM, 25nM, and 50nM) were utilized and assays at each dose were run ten times.
CXCR4 Receptor Activation Assay
Fourteen day EPCs cultured in endothelial specific media on vitronectin coated plates were
trypsinized and plated onto the bottom of a 96-well cell culture plate at a density of 10,000
cells per well and allowed to adhere for 24hrs. Cells were incubated with culture media
containing recombinant SDF (0.5ug/mL) or ESA (0.5ug/mL) or media only (control) for 10
minutes and subsequently fixed in 4% formaldehyde. Phosphorylated and total AKT levels
were quantified using FACE AKT ELISA Kit (Active Motif). These experiments were also
repeated out with the addition of the CXCR4 receptor antagonist AMD3100 to each
experimental group. Results are reported in optical density (OD) units.
CXCR4 Receptor Expression
EPCs were seeded overnight at a density of 1 × 104 cells per cover slip in four well slide
chambers. Cells were either treated with 100 ng/ml SDF or 100 ng/ml ESA at 37°C for six

Circulation. Author manuscript; available in PMC 2014 August 18.

Hiesinger et al.

Page 5

hours. Following chemokine stimulation, the cells were fixed and immunostained with
rabbit anti-CXCR4 antibody (Abcam) at 1:250 for 12 hours. Cells were then incubated with
Alexa 488 donkey anti-rabbit polyclonal antibody (Invitrogen) at 1:250 for one hour at room
temperature. The cells were counterstained with DAPI to visualize nuclei. The
immunofluorescence images were acquired using Zeiss ZEN 2010 software and a Zeiss
LSM 710 confocal laser fluorescence scanning microscope.
Animal Care and Biosafety
Male CD-1 mice weighing 25 - 30 g were obtained from Charles River. Food and water
were provided ad lib. This investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health (NIH Publication No.
85-23, revised 1996) and was approved by the Institutional Animal Use and Care Committee
of the University of Pennsylvania (Protocol #709026).
Ischemic Cardiomyopathy Model
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), intubated with
a 22-gauge catheter, and mechanically ventilated (Hallowell EMC). With the animal supine,
an anterior thoracotomy was performed in the left fourth intercostal space, and an 8-0
polypropylene suture was placed around the mid-left anterior descending coronary artery
(LAD) midway between the left atrial appendage and left ventricular apex and ligated to
produce a large anterolateral myocardial infarction of 30% of the left ventricle. The extent of
infarction is highly reproducible in our hands and progression to cardiomyopathy has been
well documented. Following ligation, animals were randomly assigned to receive direct
intramyocardial injection into the peri-infarct borderzone of either saline (30 μl, n=7), SDF
(6μg/kg in 30 μl, n=13), or ESA (6μg/kg in 30 μl, n=10). The thoracotomy was then closed
and the animals were extubated and recovered. Buprenorphine (0.5mg/kg) was administered
for postoperative analgesia. Both treatment groups received subcutaneous injections of 40
μg/kg liquid sargramostim (GMCSF), diluted in saline for a total volume of 100 l
immediately postoperatively and on postoperative day one.
In Vivo Angiogenic Growth Factor Expression
To assess upregulation of angiogenic growth factors and evaluate any potential sustained
angiogenic effect of ESA treatment, hearts from all animals (Control n=7, SDF n=13, and
ESA n=10) were explanted two weeks following LAD ligation, and myocardial tissue
biopsies were taken from the ischemic borderzone. Samples were homogenized in T-Per
Tissue Extraction Reagent (Thermo-Fischer), normalized for total protein content via Quick
Start Bradford Protein Assay (Bio-Rad Laboratories), and tested for presence of mouse
Angiopoietin-1. Immunoblotting was performed using a mouse monoclonal antibody
directed against mouse Angiopoietin-1 (1:250, Abcam), and Horseradish peroxidase
conjugated sheep anti-mouse IgG ECL secondary antibody (1:20,000, GE Healthcare).
Chemiluminescent SuperSignal West Dura Extended Duration Substrate (Thermo Scientific)
was used and images were captured using a ChemiDoc XRS+ system (Bio Rad). Assays
were performed in triplicate.
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In Vivo Inflammatory Analysis
To assess upregulation of inflammatory factors, hearts from all animals (Control n=7, SDF
n=13, ESA n=10) were explanted two weeks following LAD ligation, and myocardial tissue
biopsies were taken from the ischemic borderzone. Samples were homogenized in T-Per
Tissue Extraction Reagent (Thermo-Fischer), normalized for total protein content via Quick
Start Bradford Protein Assay (Bio-Rad Laboratories), and tested for presence of mouse
tumor necrosis factor alpha (TNFα). Immunoblotting was performed using a rabbit
polyclonal antibody directed against mouse TNFα (1:1000, Abcam), and Horseradish
peroxidase conjugated sheep anti-rabbit IgG ECL secondary antibody (1:3000, GE
Healthcare). Chemiluminescent SuperSignal West Dura Extended Duration Substrate
(Thermo Scientific) was used and images were captured using a ChemiDoc XRS+ system
(Bio Rad).
To further assess the inflammatory response following treatment, hearts from a subset of
animals (control, n=4; SDF, n=4; ESA, n=4) were explanted two weeks after LAD ligation,
and myocardial tissue biopsies were taken from the ischemic borderzone. Samples were
homogenized in T-Per Tissue Extraction Reagent (Thermo-Fischer), normalized for total
protein content via Quick Start Bradford Protein Assay (Bio-Rad Laboratories), and tested
for presence of multiple inflammatory markers including MCP-1, SCF, NF-κB, phosphoNF-κB, phospho-p38 MAPK, phospho-Stat3, and phospho-IκB-α. Levels were quantified
using the Mouse Inflammation ELISA Strip (Signosis, Sunnyvale) and the PathScan
Inflammation Multi-Target Sandwich ELISA (Cell signaling Technology, Danvers).
Echocardiographic Assessment of LV Geometry and Function
Left ventricular (LV) geometry and function were evaluated at 2 weeks (Control n=7, SDF
n=13, ESA n=10) following LAD ligation using a high-resolution (30 MHz) Vevo 770
transthoracic echocardiography system (VisualSonic Inc., Toronto, Canada). Four-equallyspaced short-axis and one maximum long-axis cine-loop acquisitions of the left ventricle
(LV) were recorded with ultrahigh-frame-rate EKVTM (ECG-based kilohertz visualization)
acquisition mode. The LV systolic function was evaluated by modified 4-plane Simpson's
method. LV cross-sectional areas were obtained by tracing the diastolic and systolic
endocardial borders in each of the four equally-spaced LV short-axis slices. Based on these
measurements and the Simpson Length (d, s), the fractional area change (FAC, %), ejection
fraction (EF, %), stroke volume (SV, ul) and cardiac output (CO, ml) were computed using
the Vevo 770 Standard Measurement Package. Before and during the ultrasound scanning,
the mouse was lightly anesthetized with a mixture of 1-2% Isoflurane gas and 100% oxygen,
and was placed in the supine position on a heating platform.All analyses were performed by
a single investigator in a group blinded fashion.
Statistical Analysis
Overall comparisons between the three groups were analyzed using a oneway analysis of
variance (ANOVA). The results are reported using F (a ratio of the variance between groups
to the variance within groups), two degrees of freedom, and the p-value. In addition, the
unpaired Student's t-test was used to compare individual groups. Values are expressed as
mean ± standard error of the mean (SEM). Statistical significance was defined by P ≤ 0.05.
Circulation. Author manuscript; available in PMC 2014 August 18.
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Results
Computational Protein Design, Modeling, and Synthesis
The crystallographic structure of SDF at 2.2 Å resolution was used to guide design and
modeling (Figure 1).27 The central beta sheet region residues (amino acids 18-54) were
replaced with a two-proline linker, resulting in the 32-residue designed polypeptide ESA.
The coordinates of residues 14FESHPPL20 were allowed to relax upon modeling with
MODELLER while the coordinates of the remainder of the structure were constrained at
their crystallographic values. Fifty different possible structures were generated for peptides
with a one, two, or three proline linker. In general, the number of stable conformations
increases substantially as the number of linking amino acids is increased (Figure 2). The
peptide with the two proline linker (subsequently designated ESA) yielded energetic and
conformational advantages. The ESA peptide structure model with the lowest scoring
function was chosen for further analysis. Importantly, the two proline residues were found to
have energetically favorable backbone dihedral angles (φ and ψ) consistent with those
observed for proline in natural protein structures (Figure 3). The introduction of a two
consecutive proline linker does not produce steric clashes within the modeled polypeptide
structure. In addition, based on the calculated structure, phenylalanine 14 (F14ESA) is
interacting with glutamic acid 15 (E15ESA), histidine 17 (H17ESA) and leucine 20 (L20ESA
or L55 in SDF). These interactions are not present in the crystallographic structure of SDF
and this group of residues may form a small cluster-like structure which, when coupled with
the diproline spacer, bias the peptide toward conformations similar to those found in native
SDF (Figure 4). Further structural analysis reveals that the model doesn't contain any steric
clashes or unusual conformations of the backbone and the amino acid side chains.
EPCs Cultured in Endothelial Specific Media Exhibit Enhanced Migration When Exposed to
an ESA gradient
Utilizing a Boyden chamber assay, 14 day cells show increased migration when placed in an
ESA gradient when compared to both recombinant SDF and saline (ESA 567±74 cells/HPF
vs. SDF 438±46, p=0.037 cells/HPF; vs. control 156±45 cells/HPF, p=0.001).
Representative slides are shown in Figure 5. In addition, a one-way ANOVA was used to
generate an overall comparison of the three study groups. EPC migration differed
significantly across the three groups, F (2, 6) = 41.27, p = 0.0003. A dose response curve
generated by comparing molar equivalents of ESA and SDF (Figure 6) demonstrated that
ESA significantly outperforms SDF at the high end of the concentration range but was
essentially equivalent to SDF for the low and mid range concentrations. Additionally, it was
revealed that the effectiveness of ESA and SDF are not linearly correlated to the dose
concentration and that there is a significant decrease in EPC migration at the very highest
doses for both.
ESA Elicits Increased CXCR4 Receptor Activation In Vitro
Cells treated with ESA had greater levels of AKT phosphorylation than both recombinant
SDF (1.638 ± 0.239 OD vs. 1.258 ± 0.187 OD, p=0.006) and control (1.638 ± 0.239 OD vs.
0.949 ± 0.077 OD, p=0.0003). There was no significant difference in total AKT content
across all groups. In addition, a one-way ANOVA was used to generate an overall
Circulation. Author manuscript; available in PMC 2014 August 18.
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comparison of the three study groups. Levels of AKT phosphorylation differed significantly
across the three groups, F (2, 21) = 38.56, p < 1 × 10−7. The addition of the CXCR4 receptor
antagonist AMD3100 to the culture media eliminated any difference in receptor activation
between the groups (ESA 0.598 ± 0.22 OD vs. SDF 0.599 ± 0.07 OD, p=0.49 and ESA
0.598 ± 0.22 OD vs. Control 0.539 ± 0.05 OD, p=0.27).
EPCs Display Robust CXCR4 Expression When Treated With ESA
Following exposure to ESA or SDF for six hours, isolated EPCs demonstrate diffuse
expression of the CXCR4 receptor (Figure 7).
In vivo Angiogenic Growth Factors Are Upregulated by ESA
At two weeks, immunoblotting revealed a significant quantitative increase in mouse
Angiopoietin-1 expression in the ESA and SDF treated animals compared to the control
group. Quantitative analysis demonstrated intensities of 336 ± 9 (ESA), 367 ± 17 (SDF), and
234 ± 7 (control) intensity units, respectively (p<0.001). A representative immunoblot is
shown in Figure 8.
In vivo Levels of Borderzone Inflamatory Markers Are Not Statistically Different between
Groups
At two weeks, immunoblotting revealed similar levels of TNFα between the ESA, SDF, and
control groups. Quantitative analysis demonstrated intensities of 4784 ± 274 (ESA), 4832 ±
547 (SDF), and 4832 ± 722 (control) arbitrary intensity units, respectively. Statistical
comparisons revealed no statistically significant difference (ESA vs. control, p=0.46; ESA
vs. SDF, p=0.4, SDF vs. control, p=0.5). Additional analysis demonstrates that, following
infarction and treatment, borderzone levels of the inflammatory factors MCP-1, SCF, NFκB, phospho-NF-κB, phospho-p38 MAPK, phospho-Stat3, and phospho-IκB-α are either
NOT significantly different or significantly less in animals treated with ESA or SDF when
compared to saline control animals. These findings indicate that inflammation is not
responsible for the beneficial and pro-angiogenic effects of ESA.
Echocardiographic Assessment Demonstrates Enhanced LV Function Following ESA
Treatment
Echocardiographic assessment of cardiac function demonstrated significant benefits in the
ESA group compared to the control group. At two weeks, ESA animals had a significantly
improved ejection fraction (57 ± 2.9% vs. 42 ± 1.6%, p=0.002), cardiac output (30 ± 1.8
ml/min vs. 23 ± 1.3 ml/min, p=0.01), stroke volume (61 ± 3.6μl vs. 48 ± 2.9μl, p=0.02), and
fractional area change (52 ± 3.6% vs. 29 ± 4.9%, p=0.001) when compared to controls. The
ESA treated mice also had a significantly increased fractional area change when compared
to SDF treated mice (52 ± 3.6% vs. 42 ± 3.2%, p=0.04) and a strong trend towards
improvement in all other ventricular function parameters assessed [See Table 1]. A one-way
ANOVA was used to generate an overall comparison of the three study groups for each
cardiac functional parameter. Values differed significantly across the three groups for
ejection fraction (F (2, 27) = 5.71, p = 0.009), cardiac output (F (2, 27) = 3.98, p = 0.03),
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stroke volume (F (2, 27) = 3.83, p = 0.03), and fractional area change (F (2, 27) = 7.91, p =
0.002).

Discussion
Angiogenic cytokine therapy for ischemic heart disease has proven to have great potential in
numerous pre-clinical and clinical trials. The ability to replenish myocardial
microvasculature could prove life saving to the millions of patients with myocardial
ischemia. SDF, in particular, is among the most potent and specific angiogenic cytokines; its
sole target, the CXCR4 cell surface antigen, is expressed in significant levels on CD34+
EPCs and expression of this receptor is related to efficient SDF induced transendothelial
migration.28 SDF has been shown repeatedly to play a critical role in the rescue of
myocardial function and stem cell recruitment to the heart after myocardial
infarction.19, 20, 29-33 However, significant barriers remain between the diverse experimental
success of SDF angiogenic cytokine therapy and its wide spread clinical translation. SDF is
a large, complex 10 kD protein that is expensive to manufacture and readily inactivated by
proteases that are upregulated at the time of myocardial infarction.34, 35 It is our belief that
smaller, synthetic analogs of SDF can provide translational advantages over the native
protein including enhanced stability and function, ease of synthesis, lower cost, and potential
modulated delivery via engineered biomaterials. In this study, we employed advanced
computational protein design techniques to create a more efficient and translatable molecule
(ESA) evolved from the native SDF protein.
The ESA peptide was engineered to link the native N-terminus (responsible for receptor
activation and binding) and the C-terminus (responsible for extracellular stabilization) with a
diproline amino acid spacer. Though ESA may not have a well-defined tertiary structure, the
linker is designed to bias the polypeptide toward structures that present the N- and C-termini
in a manner similar to that present in the native SDF protein. Based on the modeled
structure, F14ESA is in proximity to E15ESA, H17ESA and L20ESA forming a small cluster of
side chains within ESA (Figure 4). These interactions, coupled with the diproline linker,
may provide a conformational bias sufficient to recover the activity associated with SDF.
The end product, ESA, is a novel polypeptide that contains less than half of the number of
amino acid residues, is less than half of the molecular weight, and has enhanced physiologic
performance when compared to recombinant SDF.
The SDF chemotactic homing mechanism is central to its ability to increase peri-infarct
microvasculature and prevent mechanically inefficient ventricular contraction and
eventually heart failure. Utilizing a Boyden Chamber assay to directly quantify the
magnitude of cellular migration, we were able to demonstrate significantly enhanced
migration of endothelial progenitor stem cells when placed in an ESA gradient compared to
native SDF peptide. This result shows that for the same mass concentration, ESA not only
retains this important function, despite its reengineered conformation, but surpasses the
native protein. Compared to SDF, the relatively small size of ESA may enhance its diffusion
potential and the speed at which the chemotactic signal is deployed. However, rapid
diffusion is likely not the only factor that leads to significantly greater EPC migration. It has
been shown that AKT activation is required for SDF induced cellular migration.36 To
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evaluate the EPC response to ESA, we incubated EPCs with culture media containing ESA,
recombinant SDF, or media only (control) and quantified both phosphorylated and total
AKT levels by ELISA. In concordance with the results of the EPC migration assay, we were
able to demonstrate significantly increased CXCR4 receptor activation and phosphorylated
AKT levels in response to ESA when compared to SDF. Also, the addition of the CXCR4
antagonist AMD3100 eliminates this difference in receptor activation between ESA, SDF,
and control, confirming receptor specificity. It is difficult to speculate which specific
receptor-peptide interactions are responsible for the enhanced activation of CXCR4 by ESA
and future computational studies will be employed to understand the surprisingly efficient
activity of this novel polypeptide on a molecular level.
It is our belief that ESA, in a similar fashion to SDF, increases borderzone microvasculature
which, in turn, reverses cellular ischemia, preserves cardiomyocyte viability, and increases
the mechanical efficiency of peri-infarct myocardium. In support of that hypothesis, we have
shown that borderzone myocardium treated with ESA has significantly upregulated levels of
Angiopoietin-1, indicative of an ongoing angiogenic process as late as two weeks after
infarction and treatment. One could argue that the mechanism responsible for the
upregulated angiogenic activity is an exaggerated inflammatory response resulting from the
injection of ESA or even SDF. However, analysis of borderzone TNFα, MCP-1, SCF, NFκB, phospho-NF-κB, phospho-p38 MAPK, phospho-Stat3, and phospho-IκB-α, revealed
that levels of inflammatory markers are not increased in experimental animals compared to
controls indicating that the beneficial angiogenic and functional effects are not the result of
differing levels of inflammation.
An increase in microvascular perfusion should result in decreased ventricular remodeling,
improved regional ventricular function, and slower progression toward heart failure. Left
ventricular geometry and function were evaluated at 2 weeks following LAD ligation using
a high-resolution (30 MHz) transthoracic echocardiography system. The improved
functionality of ESA in vitro was, once again, borne out in vivo. Animals treated with
intramyocardial injections of the ESA peptide had better ejection fractions, cardiac output,
stroke volume, and fractional area contraction than both the SDF and control groups.
In conclusion, we have been able to engineer a novel, low molecular weight polypeptide
with the enhanced physiologic ability to induce EPC migration, EPC receptor activation, and
improve ventricular performance when compared to native SDF. This peptide offers a more
clinically translatable neovasculogenic therapy that could conceivably be deployed at any
point in the time course of ischemic heart disease to address critical deficits in microvascular
perfusion.
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Figure 1.

Crystallographic structures of SDF27 and designed model structure ESA. The different
regions of the structure are colored as, N terminal (green), central region (yellow) and C
terminal (magenta). The central β-sheet region (yellow) is replaced by a diproline linker in
ESA. The corresponding amino acid sequences of SDF-1α and ESA are also depicted,
where the different regions are colored accordingly.
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Figure 2.

Top and side view of experimental SDF analog peptides utilizing one proline (a), two
proline (b), and three proline (c) residues to link the N and C terminus. The images depict a
composite of the 50 most energetically stable conformations of each peptide sequence. The
peptide with the two proline linker (b) adopts a more uniform tertiary profile than the others
and recovers the perpendicular orientation between the N- and C- termini found in native
SDF.
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Figure 3.

All of the residues from the ESA loop or linker region are located inside favored regions in
the Ramachandran plots (bounded by the blue and purple lines) indicating allowable bond
angles. Most importantly, the two proline residues were found to have energetically
favorable backbone dihedral angles (φ and ψ) consistent with those observed in natural
protein structures.
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Figure 4.

Space-filling representation of the ESA and SDF-1α structures. The bulky side chain of
phenylalanine 14 (F14ESA) is interacting with glutamic acid 15 (E15ESA), histidine 17
(H17ESA) and to some extent with leucine 20 (L20ESA or residue 55 in native SDF-1α). The
interactions of F14SDF, E15SDF, H17SDF and L55SDF are absent in crystallographic structure
of SDF-1α.These new interactions form a small cluster-like structure which, when coupled
with the diproline spacer (yellow in ESA), may help to provide the necessary
conformational stability and rigidity found in native SDF.
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Figure 5.

Representative images of Boyden Chamber Assay filters demonstrating GFP positive EPC
migration when exposed to a saline, SDF, and ESA gradient respectively.
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Figure 6.

Dose response curve of EPC migration comparing molar equivalent concentration gradients
of ESA and SDF.

Circulation. Author manuscript; available in PMC 2014 August 18.

Hiesinger et al.

Page 20

Figure 7.

Isolated EPCs cultured and stimulated with either SDF (A and B) or ESA (C and D)
demonstrate robust and universal expression of the CXCR4 receptor (green). Nuclei are
stained with DAPI (blue).
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Figure 8.

At two weeks, borderzone myocardial tissue samples show increased levels of mouse
Angiopoietin-1 in the ESA and SDF treated groups compared to the control group.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) staining was performed to
demonstrate equivalent protein loading between lanes.

Circulation. Author manuscript; available in PMC 2014 August 18.

Hiesinger et al.

Page 22

Table 1

At two weeks, ESA treated animals demonstrated improved left ventricular function by transthoracic
echocardiography.
Modality

ESA (n=10)

Control (n=7)

SDF (n=13)

Ejection Fraction (%)

Parameter

57 ± 2.9

42 ± 1.6, p=0.002

51± 2.7, p=0.16

Fractional Area Change (%)

52 ± 3.6

29 ± 4.9, p=0.001

42 ± 3.2, p=0.04

Stroke Volume (μl)

61 ± 3.6

48 ± 2.9, p=0.02

55± 2.4, p=0.14

Cardiac Output (ml/min)

30 ± 1.8

23 ± 1.3, p=0.01

27± 1.3, p=0.29

Echo

Circulation. Author manuscript; available in PMC 2014 August 18.

